Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project by Cary, K. C. et al.
Nationally-representative trends and geographic variation in 
treatment of localized prostate cancer: the Urologic Diseases in 
America Project
K. Clint Cary1, Sanoj Punnen2, Anobel Y. Odisho4, Mark S. Litwin3, Christopher S. Saigal3, 
Matthew R. Cooperberg4, and the NIDDK Urologic Diseases in America Project
1Department of Urology, Indiana University School of Medicine
2Department of Urology, University of Miami Miller School of Medicine
3Department of Urology, University of California Los Angeles
4Department of Urology, University of California San Francisco
Abstract
Introduction—Several treatment options for clinically localized prostate cancer currently exist 
under established guidelines. We aim to assess nationally-representative trends in treatment over 
time and determine potential geographic variation using two large national claims registries.
Methods—Men with prostate cancer insured by Medicare (1998–2006) or a private insurer 
(Ingenix database, 2002–2006) were identified using ICD-9 and CPT-4 codes. Geographic 
variation and trends in the type of treatment utilized over time were assessed. Geographic data was 
mapped using the GeoCommons online mapping platform. Predictors of any treatment were 
determined using a hierarchical generalized linear mixed model using the logit link function.
Results—The use of radical prostatectomy (RP) increased, 33% to 48%, in the privately insured 
i3 database, while remaining stable at 12% in the Medicare population. There was a rapid uptake 
in the use of newer technologies over time in both the Medicare and i3 cohorts. The use of 
laparoscopic assisted prostatectomy increased from 1% in 2002 to 41% in 2006 in i3 patients, 
while the incidence increased from 3% in 2002 to 35% in 2006 for Medicare patients. The use of 
neoadjuvant/adjuvant androgen deprivation therapy (ADT) was lower in the i3 cohort and has 
decreased over time in both i3 and Medicare. Physician density had an impact on type of primary 
treatment received in the New England region, however, this trend was not seen in the Western or 
Southern regions of the United States.
Conclusion—Using two large national claims registries, we have demonstrated trends over time 
and substantial geographic variation in the type of primary treatment used for localized prostate 
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cancer. Specifically, there has been a large increase in the use of newer technologies, (i.e. 
laparoscopic-assisted prostatectomy and IMRT). These results elucidate the need for improved 
data collection on prostate cancer treatment outcomes to reduce unwarranted variation in care.
Introduction
Prostate cancer is estimated to account for nearly a third of all incident cancers in men.1 
With many therapeutic options available, localized prostate cancer treatment patterns are 
quite diverse. Some of this variation in treatment is likely explained by a lack of sufficient 
evidence to suggest a greater benefit of one treatment approach over another.2,3
Variation in treatment attributable to local practice site has been shown to range from 13% 
for primary androgen deprivation therapy to 74% for cryotherapy.4 This suggests factors 
other than cancer risk and patient characteristics may influence treatment decisions.5 
Furthermore, advances in both radiation and surgical technology have also led to changes in 
treatment patterns over time.
The aim of the current study was to confirm nationally representative trends in the use of 
primary treatment for localized prostate cancer in two large claims-based registries 
representing men across the age spectrum, and assess demographic, geographic, and clinical 
predictors of treatment.
Methods
Using the Medicare claims database, 77,216 men were identified with the diagnosis of 
prostate cancer between 1998 and 2006. Men were identified by having an International 
Classification of Diseases (ICD-9, 9th revision) code of 185 and a Current Procedural 
Terminology code (CPT-4, 4th edition) for either a prostate biopsy or transurethral resection 
of the prostate within 180 days of the ICD-9 code date. Men were excluded if they were < 
66 years of age at the time of diagnosis (n=10,157), not continuously covered by Medicare 
Part A&B (n=6,753), had Medicare managed care coverage (n=4,171), had underwent 
primary orchiectomy (n=1,073), and/or primary chemotherapy (n=90). After exclusion 
criteria, 54,322 men remained in the final Medicare analysis.
The i3 database (Ingenix, Salt Lake City, UT), a subsidiary of UnitedHealth Group, is a 
large medical claims database providing information on privately insured individuals. The i3 
database contains clinical information on patients from all 50 states and includes 
demographic characteristics, diagnoses and procedures performed via ICD-9 and CPT codes 
as well as radiologic and laboratory tests. We had access to data from 2002 through 2006 
where 63,150 men were identified with prostate cancer using the previously mentioned 
ICD-9 and CPT-4 codes. Men were excluded if they had discontinuous insurance coverage 
from 6 months before to 18 months following primary treatment (n=33,909), or treated 
primarily with orchiectomy (n=109) or chemotherapy (n=41). Thus, 16,161 men were 
included in the i3 database analysis.
Primary forms of surgical therapy included retropubic radical prostatectomy (RRP), perineal 
radical prostatectomy (PRP), and laparoscopic (+/− robot assist) radical prostatectomy 
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(LRP). Primary radiotherapy included external-beam radiation therapy (EBRT), intensity-
modulated radiation therapy (IMRT), brachytherapy (BT), and cyberknife/proton beam 
therapy. Other primary treatments included cryotherapy, primary androgen deprivation 
monotherapy (PADT) and watchful waiting/active surveillance (WW/AS). These treatments 
were assigned using CPT codes identified in the 180 days following the index diagnosis. 
Those men assigned to WW/AS were required to have a CPT code for prostate biopsy, 
transrectal ultrasound, or PSA 30 to 180 days from their index diagnosis date.
Demographic data available for both cohorts included age, race, place of residence, and 
primary treatment. Differences between the two cohorts were assessed with Pearson chi-
square methods. Summary statistics were used to assess differences in utilization of primary 
treatment. Geographic variation in radical prostatectomy, radiation therapy, and primary 
ADT utilization by urologist and radiation oncologist density was mapped in three distinct 
regions of the United States: California, New England, and Florida using the GeoCommons 
online mapping platform. These regions were selected due to the data being most robust in 
these locations and also being distinct geographic regions of the country.
To estimate the fixed effects of various clinical and demographic predictors of primary 
treatment, a hierarchical generalized linear mixed model using the logit link function 
accounting for the random effects of the counties was used to account for correlation of the 
county level data. Only counties with 30 or more prostate cancer patients were included in 
the final model to eliminate treatment outliers due to low volume counties. The model 
outcome was primary treatment of any type. All other analyses were performed using SAS 
(SAS Institute, Cary, NC) and Stata (STATA, College Station, TX) statistical software.
Results
Table 1 compares patient demographics between the two cohorts. By nature of age-based 
eligibility requirements, Medicare patients were older at diagnosis (mean age 75 vs. 64 in i3 
men). The predominant race in both Medicare and i3 patients was Caucasian. A plurality of 
patients in both cohorts resided in Southern states. As expected given the age distribution, i3 
patients received surgery at a higher proportion than Medicare patients, where as Medicare 
patients received more radiation.
Figures 1a and 1b depict the temporal trends in the type of primary treatment between each 
cohort. In the i3 population, the use of radical prostatectomy (RP) increased over time from 
33% in 2002 to 48% by 2006; the use of EBRT remained stable at around 20%. Of those 
undergoing RP, only 0.8% had minimally invasive surgery (MIS) (i.e. laparoscopic/robotic) 
in 2002, which had increased to 40.8% by 2006. Despite the use of EBRT remaining stable, 
there was an increase in the use IMRT from 21.8% to 71.1% during this time period. The 
use of BT remained stable at around 10% in the i3 cohort. Conversely, the use of RP (~12%) 
and EBRT (~31%) in the Medicare cohort remained stable during the study period. Similar 
to the i3 cohort, the utilization of MIS (0% to 35%) and IMRT (0% to 74.8%) increased in 
the Medicare sample from 1998 to 2006. There was an increase in the use of BT in Medicare 
patients from 4.6% to 12.6% over time. In both cohorts there was a decrease in the 
utilization of WW/ AS, however, this was more pronounced in the i3 cohort. There was a 
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decreased use of PADT in both cohorts. There was also limited utilization of newer radiation 
technologies such as cyberknife and proton beam therapy in both cohorts.
Variation in the use of neoadjuvant/adjuvant (neo/adjuvant) androgen deprivation therapy 
around the time of primary prostate cancer treatment was observed between the Medicare 
and i3 cohorts over time (Figure 2). In general, men in i3 received neo/adjuvant ADT at a 
lower proportion than men in Medicare regardless of type of primary treatment (i.e. RP, 
EBRT, cryotherapy). The use of neo/adjuvant ADT with primary EBRT reached its highest 
incidence in 2004, then declined through the end of the study period in both cohorts. The use 
of neo/adjuvant ADT for RP, BT, and cryotherapy declined over the entire study period.
Figure 3 shows the trends of adjuvant EBRT following RP over time in both i3 and 
Medicare. In both cohorts, the utilization of adjuvant radiation therapy is quite low; in 
Medicare it is approximately 6.5% and i3 approximately 5%. There was an increasing trend 
in the use of adjuvant EBRT in the i3 men, while relatively stable incidence in Medicare 
men over time. In the years directly comparable between Medicare and i3 (2002–2006), the 
trends differed the most between 2003 and 2004. During these years, incidence of adjuvant 
EBRT increased in i3 men and decreased in Medicare men.
Figure 4 demonstrates geographic variation in prostate cancer treatment (i.e. radical 
prostatectomy, radiation therapy, and primary ADT) by urologist and radiation oncologist 
density in three distinct regions of the United States; California, New England, and Florida. 
Proportion receiving each treatment is categorized into quintiles with lighter shades 
representing lower quintiles and darker shades higher quintiles. In New England, the 
counties with the highest urologist density had lower proportions receiving RP or PADT. 
Conversely, the counties with the highest density of radiation oncologist received higher 
proportions of radiation therapy. In California and Florida, there did not seem to be any 
discernable pattern between treatment received and urologist or radiation oncologist density. 
In the hierarchical multivariable analysis of those counties with at least 30 prostate cancer 
patients, age, comorbidity, urologist density, income level, and year of diagnosis were 
significant predictors of treatment.(Table 2)
Discussion
This study assessed national trends in the primary treatment of localized prostate cancer 
using two large claims-based registries. In both cohorts there was a decrease over time in the 
use of PADT and an increased use of newer technologies such as IMRT for radiation and 
minimally invasive surgery. There was also a reduction in the use of WW/AS in both 
cohorts, which was more pronounced in the i3 cohort. In general, men in I3 received 
neoadjuvant ADT treatments at a lower rate then men in Medicare, while both cohorts 
underwent low rates of adjuvant radiation after RP. Finally, there was substantial geographic 
variation in primary treatment selection for men with localized prostate cancer.
When comparing the Medicare and i3 cohorts we noticed that a greater proportion of men in 
i3 were receiving active local treatment compared to those managed with PADT or WW/AS. 
This is most likely related to the younger age of the I3 cohort compared to men in Medicare. 
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Previous studies have shown an association between younger age at diagnosis and the 
selection of more aggressive primary treatment.4,6 In addition, studies have shown that men 
with private insurance were more likely to undergo active treatment primarily with surgery.4 
This is similar to our findings of increased active treatment, and more specifically surgery in 
the i3 cohort, who may have better access to health care and more available options for 
management of their prostate cancer. Without data of stage and grade of disease, we were 
unable to assess the affect of disease risk on treatment selection. In both cohorts we noticed 
an increased uptake of newer technologies such as IMRT over EBRT for radiation and 
laparoscopic radical prostatectomy over open radical prostatectomy for surgery. This is 
comparable to other studies that have shown a similar adoption of newer technologies 
replacing older approaches in the contemporary management of localized prostate cancer.7
This study also assessed temporal trends in the use of neo-adjuvant ADT and found a greater 
utilization among men in Medicare, compared to those in I3 regardless of primary treatment 
modality. This finding may reflect the older age of men on Medicare. Studies has shown that 
older men are more likely to harbor aggressive disease8,9, potentially resulting in a higher 
utilization of ADT in this population. We noticed a decline over time in the use of neo-
adjuvant ADT among men undergoing RP, BT and cryotherapy in both i3 and Medicare. 
This may reflect the publication of several studies in the late 1990’s warning of the risk of 
ADT on several parameters including quality of life, cognition, bone heath and eventually 
cardiovascular and endocrine risk.10–13 Increased awareness of the potential harms of ADT 
coupled with the publication of trials questioning its benefit as a neo-adjuvant therapy in 
patients undergoing RP14 may have resulted in its declining use in these patients.
A recent study looking at trends in ADT use among men in Ontario, Canada reported a 
similar pattern of increasing ADT utilization from 1995 – 2001, followed by a sharp decline 
thereafter.15 The authors hypothesized that increased awareness of the potential adverse 
affects of ADT may have resulted in the observed decline in its use over time. Despite the 
declining use of ADT in most clinical settings that were explored in this study we did 
observe an increased utilization of neo-adjuvant ADT among men undergoing EBRT in both 
Medicare and i3. This may be impact of practice changing trials such as Bolla et al. 
published in the late 1990’s, which showed a benefit of ADT use in high-risk patients 
undergoing radiation and subsequent studies which showed similar benefits in intermediate 
risk patients.16,17
This study observed a low rate of adjuvant radiotherapy after RP in both the Medicare and i3 
cohorts. A similar trend has been seen in other studies. In the CaPSURE database adjuvant 
radiation after surgery was uncommon and declining (7.3% in 1990–1994 to 2.3% in 2004–
2007) after surgery, even among men with high-risk features.18 Despite the relatively low 
use of adjuvant radiotherapy in both cohorts, there was a trend towards increase utilization 
in the i3 population, which may reflect a more aggressive approach to management in this 
younger group of men with private insurance. The lack of a similar increase in adjuvant 
radiotherapy among men in Medicare may reflect the older age of the population, who may 
be more troubled by secondary adverse affects of their primary surgery (i.e incontinence) 
and a greater willingness to accept a less aggressive approach to management.
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This study found a considerable variation in primary treatment patterns between different 
geographic regions. Other studies have noticed similar variation in primary treatment 
patterns for prostate cancer. For instance, a study evaluating 36 clinical sites contributing to 
the CaPSURE registry found marked variation in primary treatment patterns across different 
sites, which the authors felt was not explained by case-mix variability or known patient 
factors.4 Another study evaluating 96,769 men in the SEER dataset found significant 
geographic variation nationwide in surgical, radiation, and watchful waiting treatment 
rates.19 The authors felt that non-clinical factors such as ethnicity and income had a 
significant association with watchful waiting over definitive treatment. Despite imbalances 
in access to care, patient and clinician preferences can often lead to unwarranted variation in 
primary treatment patterns.20 This supports the need for high quality comparative 
effectiveness research assessing alternatives for the primary treatment of localized prostate 
cancer.
This study has several strengths including the use of two large nationwide registries 
including thousands of men over a long period of time. By utilizing both datasets, insights 
are gained into treatment patterns for all age groups and various health insurance coverage 
plans. Many studies using only Medicare data are limited by the age restriction of men >65 
years of age, however, the inclusion of the i3 patient population allows the evaluation of 
treatment utilization in younger age categories. Interestingly, many of the treatment patterns 
in the two databases parallel one another, however, there were some differences between the 
groups. This study had some limitations that should be disclosed. One major limitation of 
the dataset was the lack of risk assessment of men in either cohort. Without knowledge of 
risk profile it is difficult to interpret any temporal or geographic variation in treatment 
pattern. However, one would expect that if geographic variation in risk profile existed, it 
would be subtle at best and would not explain all the variety seen in primary treatment 
selection. Secondly, the data included in the dataset only included information up to 2006. 
However, most newer technologies and thought processes guiding treatment have been 
introduced by this time period and trends in uptake of novel treatments could be expected to 
continue. In fact, in a 5% Medicare sample analysis, the proportion of men receiving 
intensity modulated radiation therapy (IMRT) in 2006 compared to 2008 increased from 
66.7% to 80.1%; for laparoscopic radical prostatectomy (LRP) the proportion increased 
from 46% to 59%.21 Geographic variation is unlikely to have changed substantially in the 
last few years. Finally, the dataset does not differentiate between active surveillance and 
watchful waiting. These limitations are inherent to observational research in claims-based 
datasets.
Conclusion
Using two large national claims registries, we have demonstrated significant trends over 
time and geographic variation in the type of primary treatment used for localized prostate 
cancer. Specifically, there has been a large increase in the use of newer technologies, (i.e. 
laparoscopic-assisted prostatectomy and IMRT) and decrease in the proportion of patients 
undergoing PADT and WW/AS. Additionally, substantial sociodemographic and geographic 
variation exists in primary treatment selection. These results elucidate the need for better 
Cary et al. Page 6
Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
comparative effectiveness research to allow the consideration of the relative effectiveness 
and toxicity of various treatments to prevent unwarranted variation in care.
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Figure 1. 
a. Variation in primary treatment of prostate cancer over time in i3 registry.
b. Variation in primary treatment of prostate cancer over time in the Medicare sample.
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Figure 2. 
a. Variation in the use of neoadjuvant/adjuvant treatment in prostate cancer over time in the 
i3
b. Variation in the use of neoadjuvant/adjuvant treatment in prostate cancer over time in the 
Medicare sample.
Cary et al. Page 12
Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Variation in the use of adjuvant EBRT following RP over time in both i3 and Medicare 
samples.
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Figure 4. 
Geographic variation in prostate cancer treatment by urologist and radiation oncologist 
density in California, Florida, and the Northeast
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Table 1
Baseline patient demographics of I3 and Medicare sample.
Medicare
(%)
Ingenix
(%)
p-value
Age at diagnosis: <0.01
Mean Age (SD) 75 (6.1) 64 (10.1)
<60 N/A 5,600 (35)
60–64 N/A 3,577 (22)
65–69 11,532 (21) 2,222 (14)
70–74 16,517 (30) 1,935 (12)
75 or older 26,273 (49) 2,827 (17)
Race: <0.01
White 47,313 (87) 11,202 (69)
Black 4,841 (9) 807 (5)
Asian 547 (1) 183 (1)
Hispanic 1,072 (2) 627 (4)
Other 493 (1) 84 (1)
Unknown 56 (0) 3,258 (20)
Region of Residence: <0.01
Northeast 10,849 (20) 2,094 (13)
South 20,376 (38) 6,811 (42)
Midwest 13,739 (25) 5,070 (31)
West 8,515 (15) 2,173 (14)
Other* 843 (2) 13 (0)
Primary Treatment: <0.01
RP 5,132 (10) 5,030 (31)
EBRT 12,519 (23) 2,629 (16)
Brachtherapy 3,838 (7) 1,269 (8)
Cryotherapy 271 (1) 66 (1)
ADT 8,554 (16) 1,040 (6)
WW/AS 7,287 (14) 1,400 (9)
None/Other 16,381 (29) 4,571 (29)
*
Puerto Rico, Guam, etc.
RP-Radical Prostatectomy, EBRT-External-Beam Radiotherapy, ADT-Androgen Deprivation Therapy, WW/AS-Watchful Waiting, Active 
Surveillance
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Table 2
Hierarchical multivariate logistic regression model for primary treatment of any type.
Odds Ratio
(95% CI)
P-value
Age at diagnosis 0.96
(0.95–0.96)
<0.0001
Year of Diagnosis 1.05
(1.04–1.06)
<0.0001
Race
Caucasian vs. African-American 0.94
(0.87–1.01)
0.10
Other vs. African-American 0.94
(0.82–1.07)
0.33
Charlson comorbidity
1 vs. 0 0.79
(0.74–0.83)
<0.0001
2+ vs. 0 0.53
(0.50–0.57)
<0.0001
Rural* 1.04(0.86–1.26)
0.67
Density of Primary care physicians (PCP) per county
<100 vs. >300 0.89
(0.77–1.03)
0.12
100–300 vs. >300 1.06
(0.94–1.19)
0.37
Density of Urologists per county
<10 vs. >50 1.47
(1.25–1.72)
<0.0001
10–50 vs. >50 1.28
(1.13–1.44)
<0.0001
Density of Radiation Oncologist per county
<5 vs. >25 1.04
(0.89–1.22)
0.65
5–25 vs. >25 0.93
(0.82–1.06)
0.28
Median Household Income per county (per $1000) 1
(1.0–1.0)
0.001
% uninsured per county 0.98
(0.97–0.99)
0.38
% Unemployment per county 0.99
(0.98–1.02)
0.87
% college educated per county 1.01
(0.99–1.02)
0.25
CI: Confidence interval
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*
Base group is Urban
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